Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 55, Issue 1, 2003, Pages 36-43

  Chronowski, Gregory M ^a   Wilder, Richard B ^a,b   Tucker, Susan L ^a   Ha, Chul S ^a   Younes, Anas ^a   Fayad, Luis ^a   Rodriguez, Maria A ^a   Hagemeister, Fredrick B ^a   Barista, Ibrahim ^a   Cabanillas, Fernando ^a   Cox, James D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Heart diseases; Hodgkin's disease; Radiotherapy; Second primary neoplasms

Indexed keywords

CARDIOLOGY; CHEMOTHERAPY; ONCOLOGY; RADIOTHERAPY; TOXICITY; TUMORS;

MEDIASTINAL DISEASES;

DISEASES;

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; LOMUSTINE; MITOXANTRONE; PREDNISONE; PROCAINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAPHRAGM; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM TUMOR; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; RADIATION DOSE; RADIATION FIELD; SOLID TUMOR; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HEART; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037216507     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)03915-9     Document Type: Article

References (47)

1. Donaldson S.S., Hancock S.L., Hoppe R.T. The Janeway lecture. Hodgkin's disease - finding the balance between cure and late effects. Cancer J Sci Am. 5:1999;325-333.
2. Ng A.K., Bernardo M.P., Weller E., et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 20:2002;2101-2108.
3. Maity A., Goldwein J.W., Lange B., et al. Comparison of high-dose and low-dose radiation with and without chemotherapy for children with Hodgkin's disease An analysis of the experience at the Children's Hospital of Philadelphia and the Hospital of the University of Pennsylvania . J Clin Oncol. 10:1992;929-935.
4. Oberlin O., Leverger G., Pacquement H., et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease The experience of the French Society of Pediatric Oncology . J Clin Oncol. 10:1992;1602-1608.
5. Hudson M.M., Greenwald C., Thompson E., et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol. 11:1993;100-108.
6. Bhatia S., Robison L.L., Oberlin O., et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 334:1996;745-751.
7. Swerdlow A.J., Barber J.A., Hudson G.V., et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort The relation to age at treatment . J Clin Oncol. 18:2000;498-509.
8. van Leeuwen F.E., Klokman W.J., Veer M.B., et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 18:2000;487-497.
9. Mendenhall N.P., Rodrigue L.L., Moore-Higgs G.J., et al. The optimal dose of radiation in Hodgkin's disease An analysis of clinical and treatment factors affecting in-field disease control . Int J Radiat Oncol Biol Phys. 44:1999;551-561.
10. Angelopoulou M.K., Vassilakopoulos T.P., Siakantaris M.P., et al. EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease. Leuk Lymphoma. 37:2000;131-143.
11. Loeffler M., Diehl V., Pfreundschuh M., et al. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. J Clin Oncol. 15:1997;2275-2287.
12. Eisbruch A., Kazerooni E.A., Sahijdak W.M., et al. Radiation following chemotherapy for mediastinal Hodgkin's disease The outcome of various doses for bulky tumors . Radiother Oncol. 46:1998;47-49.
13. Elconin J.H., Roberts K.B., Rizzieri D.A., et al. Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy. Int J Radiat Oncol Biol Phys. 48:2000;1097-1105.
14. Lukes R.J., Gompel L.F., Hall T.C., et al. Report of the Nomenclature Committee. Rye Classification Cancer Res. 26:1966;1311-1320.
15. Lukes R.J., Butler J.J. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 26:1966;1063-1083.
16. Mauch P., Goodman R., Hellman S. The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer. 42:1978;1039-1045.
17. Cosset J., Ferme C., Noordijk E., et al. Combined modality therapy for poor prognosis stages I and II Hodgkin's disease. Semin Radiat Oncol. 6:1996;185-195.
18. Lister T., Crowther D., Sutchliffe S., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease Cotswolds Meeting . J Clin Oncol. 7:1989;1630-1636.
19. Hagemeister F.B., Purugganan R., Fuller L., et al. Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy. Semin Hematol. 31:1994;36-43.
20. Tormo M., Terol M.J., Marugan I., et al. Treatment of stage I and II Hodgkin's disease with NOVP (mitoxantrone, vincristine, vinblastine, prednisone) and radiotherapy. Leuk Lymphoma. 34:1999;137-142.
21. Fuller L.M., Hagemeister F.B., North L.B., et al. The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage IA through IIB Hodgkin's disease Preliminary results . Int J Radiat Oncol Biol Phys. 14:1988;683-692.
22. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
23. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
24. Clayton D., Hills M. Statistical models in epidemiology. 1993;Oxford University Press, Oxford, England.
25. Mauch P.M., Kalish L.A., Marcus K.C., et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease Long-term analysis of risk factors and outcome . Blood. 87:1996;3625-3632.
26. Munker R., Grutzner S., Hiller E., et al. Second malignancies after Hodgkin's disease The Munich experience . Ann Hematol. 78:1999;544-554.
27. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease A report from the International Database on Hodgkin's Disease . Ann Oncol. 3:1992;117-128.
28. Cellai E., Magrini S.M., Masala G., et al. The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation Analysis of a series of 1524 cases consecutively treated at the Florence University Hospital . Int J Radiat Oncol Biol Phys. 49:2001;1327-1337.
29. Rodriguez M.A., Fuller L.M., Zimmerman S.O., et al. Hodgkin's disease Study of treatment intensities and incidences of second malignancies . Ann Oncol. 4:1993;125-131.
30. LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys. 31:1995;1049-1091.
31. Brincker H., Brentzen S.M. A re-analysis of available dose-response and time-dose data in Hodgkin's disease. Radiother Oncol. 30:1994;227-230.
32. Vijayakumar S., Myrianthopoulos L.C. An updated dose-response analysis in Hodgkin's disease. Radiother Oncol. 24:1992;1-13.
33. Hodgson D.C., Tsang R.W., Wells W., et al. The impact of chest wall involvement on the outcome of clinical stage I/II Hodgkin's disease treated with combined modality therapy. Int J Radiat Oncol Biol Phys. 48:2000;331-332. (Abstr.).
34. Kostakoglu L., Goldsmith S.J. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma Is it time to shift gears? Eur J Nucl Med. 27:2000;1564-1578.
35. Wirth A., Seymour J.F., Hicks R.J., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med. 112:2002;262-268.
36. Hoppe R.T. Hodgkin's disease Complications of therapy and excess mortality . Ann Oncol. 8:1997;115-118.
37. Hancock S.L., Heidenreich P.A., Schnittger I., et al. Screening for cardiovascular disease after Hodgkin's disease therapy. Leuk Lymphoma. 42:2001;18.
38. Brusamolino E., Anselmo A.P., Klersy C., et al. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy A case-control study . Haematologica. 83:1998;812-823.
39. Hancock S.L., Hoppe R.T. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol. 6:1996;225-242.
40. Engert A., Schiller P., Pfistner B., et al. Involved (IF) radiotherapy is as effective as extended field (EF) radiotherapy after 2 cycles of COPP/ABVD in patients (pts) with intermediate-stage Hodgkin's disease (HD) A randomized multicenter study . Blood. 98:2001;768a. (Abstr. 3199).
41. Bonfante V., Viviani S., Devizzi L., et al. Ten-years experience with ABVD plus radiotherapy Subtotal nodal (STNI) vs involved field (IFRT) in early-stage Hodgkin's disease (Hd) . J Clin Oncol. 20:2001;281a. (Abstr. 1120).
42. Hancock S., Tucker M., Hoppe R. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 85:1993;25-31.
43. Boivin J.F., O'Brien K. Solid cancer risk after treatment of Hodgkin's disease. Cancer. 61:1988;2541-2546.
44. Swerdlow A., Douglas A., Vaughan H.G., et al. Risk of second primary cancers after Hodgkin's disease by type of treatment Analysis of 2486 patients in the British National Lymphoma Investigation . BMJ. 304:1992;1137-1143.
45. Aisenberg A.C., Finkelstein D.M., Doppke K.P., et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer. 79:1997;1203-1210.
46. Jox A., Sieber M., Wolf J., et al. Hodgkin's disease-new treatment strategies toward the cure of patients. Cancer Treat Rev. 25:1999;169-176.
47. NCCN practice guidelines for Hodgkin's disease. National Comprehensive Cancer Network. Oncology. 13:1999;78-110.